• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生物制药质量控制分析方法中的风险分析模型

A Model of Risk Analysis in Analytical Methodology for Biopharmaceutical Quality Control.

作者信息

Andrade Cleyton Lage, Herrera Miguel Angel De La O, Lemes Elezer Monte Blanco

机构信息

Bio-Manguinhos/Fiocruz, Instituto de Tecnologia em Imunobiológicos, Rio de Janeiro, Brasil

Bio-Manguinhos/Fiocruz, Instituto de Tecnologia em Imunobiológicos, Rio de Janeiro, Brasil.

出版信息

PDA J Pharm Sci Technol. 2018 May-Jun;72(3):317-331. doi: 10.5731/pdajpst.2016.007286. Epub 2018 Feb 14.

DOI:10.5731/pdajpst.2016.007286
PMID:29444996
Abstract

One key quality control parameter for biopharmaceutical products is the analysis of residual cellular DNA. To determine small amounts of DNA (around 100 pg) that may be in a biologically derived drug substance, an analytical method should be sensitive, robust, reliable, and accurate. In principle, three techniques have the ability to measure residual cellular DNA: radioactive dot-blot, a type of hybridization; threshold analysis; and quantitative polymerase chain reaction. Quality risk management is a systematic process for evaluating, controlling, and reporting of risks that may affects method capabilities and supports a scientific and practical approach to decision making. This paper evaluates, by quality risk management, an alternative approach to assessing the performance risks associated with quality control methods used with biopharmaceuticals, using the tool This tool provides the possibility to find the steps in an analytical procedure with higher impact on method performance. By applying these principles to DNA analysis methods, we conclude that the radioactive dot-blot assay has the largest number of critical control points, followed by quantitative polymerase chain reaction, and threshold analysis. From the analysis of hazards (i.e., points of method failure) and the associated method procedure critical control points, we conclude that the analytical methodology with the lowest risk for performance failure for residual cellular DNA testing is quantitative polymerase chain reaction. In order to mitigate the risk of adverse events by residual cellular DNA that is not completely cleared from downstream production processes, regulatory agencies have required the industry to guarantee a very low level of DNA in biologically derived pharmaceutical products. The technique historically used was radioactive blot hybridization. However, the technique is a challenging method to implement in a quality control laboratory: It is laborious, time consuming, semi-quantitative, and requires a radioisotope. Along with dot-blot hybridization, two alternatives techniques were evaluated: threshold analysis and quantitative polymerase chain reaction. Quality risk management tools were applied to compare the techniques, taking into account the uncertainties, the possibility of circumstances or future events, and their effects upon method performance. By illustrating the application of these tools with DNA methods, we provide an example of how they can be used to support a scientific and practical approach to decision making and can assess and manage method performance risk using such tools. This paper discusses, considering the principles of quality risk management, an additional approach to the development and selection of analytical quality control methods using the risk analysis tool This tool provides the possibility to find the method procedural steps with higher impact on method reliability (called critical control points). Our model concluded that the radioactive dot-blot assay has the larger number of critical control points, followed by quantitative polymerase chain reaction and threshold analysis. Quantitative polymerase chain reaction is shown to be the better alternative analytical methodology in residual cellular DNA analysis.

摘要

生物制药产品的一个关键质量控制参数是残留细胞DNA的分析。为了测定生物来源药物中可能存在的少量DNA(约100皮克),分析方法应灵敏、稳健、可靠且准确。原则上,有三种技术能够测量残留细胞DNA:放射性斑点杂交法(一种杂交类型)、阈值分析和定量聚合酶链反应。质量风险管理是一个系统的过程,用于评估、控制和报告可能影响方法性能的风险,并支持科学实用的决策方法。本文通过质量风险管理,评估了一种用于评估生物制药质量控制方法相关性能风险的替代方法,使用了该工具。该工具提供了找出对方法性能影响较大的分析程序步骤的可能性。通过将这些原则应用于DNA分析方法,我们得出结论,放射性斑点杂交法的关键控制点数量最多,其次是定量聚合酶链反应,然后是阈值分析。通过对危害(即方法失败点)和相关方法程序关键控制点的分析,我们得出结论,残留细胞DNA检测中性能失败风险最低的分析方法是定量聚合酶链反应。为了降低下游生产过程中未完全清除的残留细胞DNA导致不良事件的风险,监管机构要求该行业确保生物来源药品中的DNA含量极低。历史上使用的技术是放射性印迹杂交法。然而,该技术在质量控制实验室中实施具有挑战性:它费力、耗时、半定量且需要放射性同位素。除了斑点杂交法,还评估了两种替代技术:阈值分析和定量聚合酶链反应。应用质量风险管理工具对这些技术进行比较,同时考虑不确定性、情况或未来事件的可能性及其对方法性能的影响。通过用DNA方法说明这些工具的应用,我们提供了一个示例,展示了它们如何用于支持科学实用的决策方法,并使用此类工具评估和管理方法性能风险。本文结合质量风险管理原则,讨论了使用风险分析工具开发和选择分析质量控制方法的另一种方法。该工具提供了找出对方法可靠性影响较大的方法程序步骤(称为关键控制点)的可能性。我们的模型得出结论,放射性斑点杂交法的关键控制点数量最多,其次是定量聚合酶链反应和阈值分析。定量聚合酶链反应被证明是残留细胞DNA分析中更好的替代分析方法。

相似文献

1
A Model of Risk Analysis in Analytical Methodology for Biopharmaceutical Quality Control.生物制药质量控制分析方法中的风险分析模型
PDA J Pharm Sci Technol. 2018 May-Jun;72(3):317-331. doi: 10.5731/pdajpst.2016.007286. Epub 2018 Feb 14.
2
The application of quality risk management to the bacterial endotoxins test: use of hazard analysis and critical control points.
PDA J Pharm Sci Technol. 2013 Sep-Oct;67(5):553-67. doi: 10.5731/pdajpst.2013.00938.
3
Multiproduct Resin Reuse for Clinical and Commercial Manufacturing-Methodology and Acceptance Criteria.用于临床和商业制造的多产品树脂再利用——方法与验收标准
PDA J Pharm Sci Technol. 2018 Nov-Dec;72(6):584-598. doi: 10.5731/pdajpst.2016.007245. Epub 2018 Jul 20.
4
Risk-based approach for method development in pharmaceutical quality control context: A critical review.基于风险的方法在药物质量控制领域的方法开发:批判性评价。
J Pharm Biomed Anal. 2018 Nov 30;161:110-121. doi: 10.1016/j.jpba.2018.07.050. Epub 2018 Jul 30.
5
Risk management frameworks for human health and environmental risks.人类健康与环境风险的风险管理框架。
J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. doi: 10.1080/10937400390208608.
6
Development of quality-by-design analytical methods.质量源于设计分析方法的开发。
J Pharm Sci. 2011 Mar;100(3):797-812. doi: 10.1002/jps.22325. Epub 2010 Sep 9.
7
Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.设备与分析公司面临持续挑战。2014年5月20 - 21日 连续制造研讨会
J Pharm Sci. 2015 Mar;104(3):821-31. doi: 10.1002/jps.24282. Epub 2014 Dec 1.
8
Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification头部损伤的转化代谢组学:基于体外核磁共振波谱的代谢物定量分析探索脑代谢功能障碍
9
Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.连续制药生产中的控制系统工程。2014年5月20 - 21日,连续制造研讨会
J Pharm Sci. 2015 Mar;104(3):832-9. doi: 10.1002/jps.24311. Epub 2014 Dec 26.
10
Lifecycle management in pharmaceutical analysis: How to establish an efficient and relevant continued performance monitoring program.药物分析中的生命周期管理:如何建立高效且相关的持续性能监测计划。
J Pharm Biomed Anal. 2020 Mar 20;181:113051. doi: 10.1016/j.jpba.2019.113051. Epub 2019 Dec 19.

引用本文的文献

1
Rheology of Complex Topical Formulations: An Analytical Quality by Design Approach to Method Optimization and Validation.复杂局部用制剂的流变学:一种基于质量源于设计的分析方法优化与验证途径
Pharmaceutics. 2023 Jun 24;15(7):1810. doi: 10.3390/pharmaceutics15071810.